



US 20210269553A1

(19) **United States**(12) **Patent Application Publication**
NG et al.(10) **Pub. No.: US 2021/0269553 A1**(43) **Pub. Date: Sep. 2, 2021**(54) **METHODS USING MONOVALENT ANTIGEN
BINDING CONSTRUCTS TARGETING HER2**(71) Applicant: **Zymeworks Inc.**, Vancouver (CA)(72) Inventors: **Gordon Yiu Kon NG**, Vanouver (CA);
Nina E. WEISSER, Delta (CA); **Grant
Raymond WICKMAN**, Vancouver
(CA)(21) Appl. No.: **17/125,601**(22) Filed: **Dec. 17, 2020****Related U.S. Application Data**(63) Continuation of application No. 15/036,175, filed on
May 12, 2016, now abandoned, filed as application
No. PCT/US2014/065571 on Nov. 13, 2014.(60) Provisional application No. 61/903,839, filed on Nov.
13, 2013.**Publication Classification**(51) **Int. Cl.****C07K 16/32** (2006.01)**C07K 16/30** (2006.01)**A61K 47/68** (2006.01)**A61K 39/395** (2006.01)(52) **U.S. Cl.**CPC **C07K 16/32** (2013.01); **C07K 16/30**(2013.01); **A61K 2039/507** (2013.01); **A61K****39/39558** (2013.01); **C07K 16/3069** (2013.01);**A61K 47/6855** (2017.08)

(57)

ABSTRACT

Provided herein are methods of use and treatment using a first or a first and second monovalent antigen-binding constructs targeting HER2. The monovalent antigen-binding constructs can include at least one antigen-binding polypeptide comprising a heavy chain variable domain, wherein the antigen-bind polypeptide specifically binds HER2; and a heterodimeric Fc, the Fc comprising at least two CH3 sequences, wherein the Fc is coupled, with or without a linker, to the antigen-binding polypeptide.

Specification includes a Sequence Listing.